帕歌斯联合柳氮磺胺吡啶治疗强直性脊柱炎的临床疗效  

The Clinical Effect of Pagosid Associated with Salicylazosulfapyridine in Treatment on Patients with Ankylosing Spondylitis

作　　者：耿云光[1] 赵清叶 李林生[1] 杜雯 

机构地区：[1]新乡医学院第一附属医院疼痛科,453100 [2]青岛市中心医院肿瘤科,266042

出　　处：《中国医药指南》2010年第13期179-180,共2页Guide of China Medicine

摘　　要：目的观察帕歌斯联合柳氮磺胺吡啶治疗强直性脊柱炎的临床疗效及不良反应。方法将确诊为强直性脊柱炎的70名患者随机分为治疗组(帕歌斯)与对照组(双氯氛酸钠),治疗组36例接受帕歌斯+柳氮磺胺吡啶口服治疗,对照组34例接受戴芬+柳氮磺胺吡啶治疗,观察两组患者的临床疗效和不良反应。结果治疗3个月后,治疗组:显效12例(33%),有效18例(50%),改善4例(11%);对照组:显效10例(29.4%),有效15例(44%),改善5例(14.7%),两组比较无统计学意义(P>0.05),治疗组不良反应较对照组少,有显著性差异(P<0.05)。结论帕歌斯联合柳氮磺胺吡啶呤治疗强直性脊柱炎疗效佳,安全性好。Objective To explore the effect and side effect of pagosid associated with Salicylazosulfapyridine （SASP）in treatment on patients with ankylosing spondylitis （AS）. Method Seventy patients were randomly divided into the study group （n=36） and the control group （n=34）. In the study group the patients were received the treatment of pagosid and Salicylazosulfapyridine （SASP）, thirty-four patients were received the treatment of Diclofenac Sodium and Salicylazosulfapyridine（SASP） in the control group; toxicity, clinical effect were observed. Results After three months, in the study group the effect was excellent in 12cases （33%）, good in 18 cases （50%）, alleviated in 4 cases （11%）and in the control group the effect was excellent in 10 cases（29.4%）, good in 15 cases （44%）, alleviated in 5 cases （14.7%）, there was no significant difference between two groups（P0.05）.The side effect of the study group was less than that of the control group ,there were extremely obvious differences in side effects （P0.01）. Conclusion The treatment of pagosid associated with SASP is effective and safe in ankylosing spondylitis （AS ）patients, and the incidence rate of side effect is low.

关 键 词：帕歌斯 柳氮磺胺吡啶 强直性脊柱炎 

分 类 号：R593.23[医药卫生—内科学]